Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 334

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 334
---
 tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2024 and 2023. There was income tax expense for the years ended December 31, 2024 and 2023 of $ 3,768and $ 0, respectively. Note 12-Stockholders’equity Immediately prior to the closing of the Merger, all outstanding shares of Company preferred stock were converted into shares of Company common stock (which were converted into shares of Kintara common stock in the Merger), and upon completion of the merger, all warrants of the Company were converted into warrants to purchase Kintara common stock. All outstanding shares of the Company’s Preferred Stock were converted into 16,912,843shares of common stock. As of December 31, 2024, the Company had two classes of stock defined in its Amended and Restated Articles of Incorporation (the “Articles). Common Stock -The Company is authorized to issue up to 75,000,000shares of Common Stock based on the Articles. Holders of common stock are entitled to one vote for each share of common stock. As of December 31, 2024, there were 42,323,759shares of common stock outstanding, of which 4,730are unregistered shares of warrants exercised after the merger. Preferred Stock -The Company is authorized to issue up to 5,000,000shares of Preferred Stock based on the Articles. The historical Kineta Series A Preferred Stock were assumed from the merger and outstanding and have a stated value of $ 278,530as of December 31, 2024. Warrants -The following table summarizes the Company’s outstanding common stock warrants as of December 31, 2024. F-8 9

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

|                                                        |     | Outstanding |            |     | Weightedaverageexercise price |          |     | Expiration dates |
|